Why do you think they should skip liver cancer? Looks a big market especially Asia , yes crowded space competition with other treatments but a small segment of big market is still worthwhile imo
agree with you point about add on, for example combine with immunotherapy (checkpoint inhibitor) is possible I think I heard somebody mentioning this once somewhere possibly old investor call
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(16.7%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $2.867K | 573.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4186862 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 15328756 | 23 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |